{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T23:20:33Z","timestamp":1756682433868,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Dublin, Trinity College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myositis-specific antibodies (MSA) and myositis-associated antibodies (MAA) are a feature of the idiopathic inflammatory myopathies (IIM), but are also seen in other rheumatic diseases, and in individuals with no clinical symptoms. The aim of this study was to assess the clinical utility of MSA and MAA and in particular the clinical relevance of weakly positive results. We included all patients at our institution who had at least one positive result on the Immunoblot EUROLINE myositis panel over a 6-year period (2015\u20132020). Associations with clinical features and final diagnosis were evaluated. Eighty-seven of 225 (39%) myositis panel tests met the inclusion criteria. There were 52 strong positives and 35 weak positives for one or more MSA\/MAAs. Among the strong positive group, 15% (8\/52) were diagnosed with IIM, 34.6% (18\/52) with interstitial lung disease, 7.7% (4\/52) with anti-synthetase syndrome, 25% (13\/52) with connective tissue disease, and others accounted for 25% (13\/52). In weak-positive cases, only 14% (5\/35) had connective tissue disease and none had IIM. 60% (21\/35) of weak-positive cases were not associated with a specific rheumatic disease. A significant number of positive myositis panel results, particularly weak positives, are not associated with IIM or CTD.<\/jats:p>","DOI":"10.1007\/s00296-021-05012-0","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T11:46:32Z","timestamp":1633434392000},"page":"2133-2146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of extended myositis panel results, clinical features, and diagnoses: a single-center retrospective observational study"],"prefix":"10.1007","volume":"41","author":[{"given":"Shamma Ahmad","family":"Al Nokhatha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Alfares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niall","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-3362","authenticated-orcid":false,"given":"Richard","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"5012_CR1","volume-title":"Kelley\u2019s textbook of rheumatology","author":"G Firestein","year":"2017","unstructured":"Firestein G, Budd R, Gabriel S, McInnes I, O\u2019Dell J (2017) Kelley\u2019s textbook of rheumatology. Elsevier, Philadelphia"},{"key":"5012_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","volume":"54","author":"A Meyer","year":"2015","unstructured":"Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J (2015) Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford) 54:50\u201363. https:\/\/doi.org\/10.1093\/rheumatology\/keu289","journal-title":"Rheumatology (Oxford)"},{"key":"5012_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/nejm197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344\u2013347. https:\/\/doi.org\/10.1056\/nejm197502132920706","journal-title":"N Engl J Med"},{"key":"5012_CR4","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dank\u00f3 K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O\u2019Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955\u20131964. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"key":"5012_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","volume":"68","author":"MG Cruellas","year":"2013","unstructured":"Cruellas MG, Viana Vdos S, Levy-Neto M, Souza FH, Shinjo SK (2013) Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics (Sao Paulo) 68:909\u2013914. https:\/\/doi.org\/10.6061\/clinics\/2013(07)04","journal-title":"Clinics (Sao Paulo)"},{"key":"5012_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","volume":"5","author":"A Ghirardello","year":"2014","unstructured":"Ghirardello A, Borella E, Beggio M, Franceschini F, Fredi M, Doria A (2014) Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights 5:69\u201375. https:\/\/doi.org\/10.1007\/s13317-014-0060-4","journal-title":"Auto Immun Highlights"},{"key":"5012_CR7","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2169\/internalmedicine.55.5774","volume":"55","author":"H Chino","year":"2016","unstructured":"Chino H, Sekine A, Baba T, Iwasawa T, Okudela K, Takemura T, Itoh H, Sato S, Suzuki Y, Ogura T (2016) Radiological and pathological correlation in anti-MDA5 antibody-positive interstitial lung disease: rapidly progressive perilobular opacities and diffuse alveolar damage. Intern Med (Tokyo, Japan). 55:2241\u20132246. https:\/\/doi.org\/10.2169\/internalmedicine.55.5774","journal-title":"Intern Med (Tokyo, Japan)."},{"key":"5012_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.autrev.2014.01.022","volume":"13","author":"M Mahler","year":"2014","unstructured":"Mahler M, Miller FW, Fritzler MJ (2014) Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13:367\u2013371. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.022","journal-title":"Autoimmun Rev"},{"key":"5012_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12948-018-0084-9","volume":"16","author":"B Palterer","year":"2018","unstructured":"Palterer B, Vitiello G, Carraresi A, Giudizi MG, Cammelli D, Parronchi P (2018) Bench to bedside review of myositis autoantibodies. Clin Mol Allergy 16:5. https:\/\/doi.org\/10.1186\/s12948-018-0084-9","journal-title":"Clin Mol Allergy"},{"key":"5012_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaut.2017.07.003","volume":"83","author":"WT Ma","year":"2017","unstructured":"Ma WT, Chang C, Gershwin ME, Lian ZX (2017) Development of autoantibodies precedes clinical manifestations of autoimmune diseases: a comprehensive review. J Autoimmun 83:95\u2013112. https:\/\/doi.org\/10.1016\/j.jaut.2017.07.003","journal-title":"J Autoimmun"},{"key":"5012_CR11","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1093\/rheumatology\/keaa055","volume":"59","author":"JB Vulsteke","year":"2020","unstructured":"Vulsteke JB, Blockmans D, Moons V, Vijgen S, Bossuyt X, De Langhe E (2020) Detection of anti-Mi-2 autoantibodies before dermatomyositis-specific manifestations. Rheumatology (Oxford) 59:e60\u2013e62. https:\/\/doi.org\/10.1093\/rheumatology\/keaa055","journal-title":"Rheumatology (Oxford)"},{"key":"5012_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/08916934.2018.1441830","volume":"51","author":"M Lecouffe-Desprets","year":"2018","unstructured":"Lecouffe-Desprets M, H\u00e9mont C, N\u00e9el A, Toquet C, Masseau A, Hamidou M, Josien R, Martin JC (2018) Clinical contribution of myositis-related antibodies detected by immunoblot to idiopathic inflammatory myositis: a one-year retrospective study. Autoimmunity 51:89\u201395. https:\/\/doi.org\/10.1080\/08916934.2018.1441830","journal-title":"Autoimmunity"},{"key":"5012_CR13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","volume":"78","author":"J Damoiseaux","year":"2019","unstructured":"Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, Garcia de la Torre I, Herold M, Klotz W, Cruvinel WM, Mimori T, von Muhlen C, Satoh M, Chan EK (2019) Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 78:879\u2013889. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214436","journal-title":"Ann Rheum Dis"},{"key":"5012_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/oarrr.S231195","volume":"12","author":"FM Alenzi","year":"2020","unstructured":"Alenzi FM (2020) Myositis specific autoantibodies: a clinical perspective. Open Access Rheumatol 12:9\u201314. https:\/\/doi.org\/10.2147\/oarrr.S231195","journal-title":"Open Access Rheumatol"},{"key":"5012_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10067-018-4267-z","volume":"38","author":"E Zampeli","year":"2019","unstructured":"Zampeli E, Venetsanopoulou A, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG, Tzioufas AG, Skopouli FN, Moutsopoulos HM (2019) Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clin Rheumatol 38:125\u2013132. https:\/\/doi.org\/10.1007\/s10067-018-4267-z","journal-title":"Clin Rheumatol"},{"key":"5012_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2019.100013","volume":"2","author":"ACM Platteel","year":"2019","unstructured":"Platteel ACM, Wevers BA, Lim J, Bakker JA, Bontkes HJ, Curvers J, Damoiseaux J, Heron M, de Kort G, Limper M, van Lochem EG, Mulder AHL, Saris CGJ, van der Valk H, van der Kooi AJ, van Leeuwen EMM, Veltkamp M, Schreurs MWJ, Meek B, Hamann D (2019) Frequencies and clinical associations of myositis-related antibodies in The Netherlands: a one-year survey of all Dutch patients. J Transl Autoimmun 2:100013. https:\/\/doi.org\/10.1016\/j.jtauto.2019.100013","journal-title":"J Transl Autoimmun"},{"key":"5012_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/rhu.0000000000001350","author":"Y Gonz\u00e1lez-Bello","year":"2020","unstructured":"Gonz\u00e1lez-Bello Y, Garcia-Valladares I, Reyes-P\u00e9rez IV, Garc\u00eda-Cerda D, Medrano-Ram\u00edrez G, Navarro-Zarza JE, Andrade-Ortega L, Maradiaga-Cece\u00f1a M, Cardenas-Anaya A, Nava-Zavala AH, Orozco-Barocio G, V\u00e1zquez-Del Mercado M, Rojo-Mejia A, Loyo E, Gottschalk P, Iglesias-Gamarra A, Vega K, Rojas C, Mantilla R, G\u00f3mez G, Garc\u00eda-Kutzbach A, Fritzler MJ, Garc\u00eda-De La Torre I (2020) Myositis-specific antibodies and myositis-associated antibodies in patients with idiopathic inflammatory myopathies from the PANLAR myositis study group. J Clin Rheumat. https:\/\/doi.org\/10.1097\/rhu.0000000000001350","journal-title":"J Clin Rheumat"},{"key":"5012_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00408-018-0108-8","volume":"196","author":"LJ De Sadeleer","year":"2018","unstructured":"De Sadeleer LJ, De Langhe E, Bodart N, Vigneron A, Bossuyt X, Wuyts WA (2018) Prevalence of myositis-specific antibodies in idiopathic interstitial pneumonias. Lung 196:329\u2013333. https:\/\/doi.org\/10.1007\/s00408-018-0108-8","journal-title":"Lung"},{"key":"5012_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.rmed.2018.02.024","volume":"137","author":"K Yoshimura","year":"2018","unstructured":"Yoshimura K, Kono M, Enomoto Y, Nishimoto K, Oyama Y, Yasui H, Hozumi H, Karayama M, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Sumikawa H, Johkoh T, Colby TV, Sugimura H, Suda T (2018) Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia. Respir Med 137:167\u2013175. https:\/\/doi.org\/10.1016\/j.rmed.2018.02.024","journal-title":"Respir Med"},{"key":"5012_CR20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/annrheumdis-2017-eular.5143","volume":"76","author":"J-B Vulsteke","year":"2017","unstructured":"Vulsteke J-B, Bossuyt X, Dillaerts D, Poesen K, Claeys K, Lenaerts J, Westhovens R, Blockmans D, Haes PD, Langhe ED (2017) FRI0393\u2005Prevalence of myositis-specific antibodies in idiopathic inflammatory myopathy compared to disease and healthy controls. Ann Rheumat Dis 76:636\u2013637. https:\/\/doi.org\/10.1136\/annrheumdis-2017-eular.5143","journal-title":"Ann Rheumat Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-05012-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-05012-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-05012-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T10:25:20Z","timestamp":1635243920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-05012-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,4]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5012"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-05012-0","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2021,10,4]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interst.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}